PerpEquities

Samsung Biologics Co., Ltd. (SSBIOLOGICS) cash flow statement

KSC · Healthcare · Biotechnology · 5,455 employees · CEO John Chongbo Rim

Price
$1,001 -0.1%
Market cap
$48.5B
Enterprise value
₩65.5T Data as of 2026-11-21
Last report
Q3 '26 filed 2026-09-30
Next report
2027-01-27 EPS est. ₩11,137.25

In Q3 '26 Samsung Biologics Co., Ltd. (SSBIOLOGICS) generated ₩409B of operating cash flow, invested ₩60.2B in capital expenditure and kept ₩352B of free cash flow. Over the last four quarters free cash flow was ₩1.45T.

Cash flow

Cash flowTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating
Net income₩291B₩179B₩318B₩264B₩321B₩376B₩324B₩574B₩340B₩469B₩431B₩391B
Depreciation & amortization₩142B₩143B₩148B₩157B₩151B₩163B₩178B₩179B₩113B₩94.6B₩112B₩111B
Change in working capital₩362B-₩124B-₩158B₩277B-₩39.9B₩152B₩117B-₩199B-₩202B₩169B₩127B-₩70.6B
Other non-cash items₩38.3B₩91.5B-₩68.9B₩42.5B-₩42.8B-₩8.47B-₩96.5B₩65.1B₩171B₩35.2B-₩45.4B-₩23.1B
Operating cash flow₩833B₩290B₩239B₩740B₩390B₩683B₩523B₩619B₩422B₩768B₩625B₩409B
Investing
Capital expenditure-₩299B-₩113B-₩104B-₩549B-₩572B-₩624B-₩135B-₩93.2B-₩555B-₩91.5B-₩99.1B-₩60.2B
Acquisitions-₩214M-₩1.87B-₩602B-₩9.86B-₩307M-₩647M₩607M-₩284M₩6.48M-₩516B-₩18B₩0
Purchases of investments-₩1.65T-₩1.05T-₩1.05T-₩407B-₩1T-₩1.1T-₩1.1T-₩200B-₩1.3T-₩1.55T-₩850B-₩842B
Sales / maturities of investments₩1.5T₩1.75T₩1.46T₩550B₩500B₩1.5T₩719B₩100B₩1T₩1.76T₩51B₩1.1T
Other investing₩131M-₩1K-₩15.3B-₩20.8B₩159M-₩24.8B-₩22.2B-₩20.3B₩0₩0₩3.5B-₩8.08M
Investing cash flow-₩450B₩585B-₩317B-₩437B-₩1.07T-₩250B-₩540B-₩214B-₩858B-₩400B-₩913B₩199B
Financing
Net debt issued / repaid-₩283B-₩133B-₩30B-₩406B₩518B₩0₩0-₩130B-₩35B-₩2.22B₩44.5B-₩164B
Share buybacks₩0₩0₩0₩0₩0₩0₩0₩0-₩92B₩0₩0₩0
Other financing (incl. tax on vested shares)-₩2.29B-₩69.8B-₩2.48B-₩308B-₩3.31B-₩69.8B-₩2.62B-₩72.3B-₩219B₩0-₩4.8B-₩7.8B
Financing cash flow-₩286B-₩202B-₩32.5B-₩713B₩514B-₩69.8B-₩2.62B-₩202B-₩346B-₩2.22B₩39.7B-₩172B
Summary
FX effect on cash-₩8.84B₩19.7B₩23.5B-₩23.2B₩21.6B-₩2.12B-₩23B₩9.31B₩8.61B₩6.35B₩16.8B-₩37.9B
Net change in cash₩88.8B₩692B-₩86.6B-₩433B-₩149B₩361B-₩42.6B₩213B-₩773B₩372B-₩232B₩397B
Free cash flow (OCF - capex)₩534B₩177B₩135B₩170B-₩183B₩33.4B₩389B₩505B-₩118B₩683B₩537B₩352B
Interest paid₩0₩0₩0₩0₩0₩0₩7.66B₩0₩0₩0₩0₩0

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in KRW.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-21 · Amounts in KRW as reported; price and market cap in USD.